Clinical Trials
5
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (80.0%)Phase 1
1 (20.0%)Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT04371718
A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule
Phase 1
- Conditions
- Autoimmune Hepatitis
- Interventions
- Drug: JKB-122 in capsule or tablet form
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
- Target Recruit Count
- 8
- Registration Number
- NCT04313205
A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis
Phase 2
- Conditions
- Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Interventions
- Drug: PlaceboDrug: Dose 1 JKB-122Drug: Dose 2 JKB-122
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT04255069
Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT02556372
- Locations
- 🇺🇸
Ruane Clinical Research Group, Inc., Los Angeles, California, United States
🇺🇸University of California Davis Medical Center - Ticon 1, Sacramento, California, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies
Phase 2
Terminated
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: JKB-122 5mgDrug: JKB-122 15mgDrug: JKB-122 35mgDrug: Placebo
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
- Target Recruit Count
- 54
- Registration Number
- NCT02293941
- Locations
- 🇨🇳
Changhua Christian Hospital, Changhua, Taiwan
🇨🇳Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi City, Taiwan
🇨🇳Chang Gung Memorial Hospital, Chiayi, Chiayi City, Taiwan
News
No news found